This study is testing a new type of immunotherapy called rondecabtagene autoleucel (ronde-cel), also known as LYL314, for people with aggressive large B-cell lymphoma (a type of blood cancer). This treatment is a CAR T-cell therapy, which means it uses your own immune cells to fight cancer. Before receiving ronde-cel, you will also receive chemotherapy drugs called fludarabine and cyclophosphamide. The study aims to see how safe ronde-cel is and how well it works to shrink tumors. You may be eligible if you are 18 or older and have received at least one or two prior treatments for your lymphoma, depending on your specific situation. The study plans to enroll about 270 participants, but its current status is unclear.

Study design

This is a Phase 1/2, multi-center, open-label study, meaning both you and your doctors will know what treatment you are receiving. It will enroll up to approximately 150 participants in the first phase to find the right dose.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will follow participants for safety and how well the treatment works for up to 24 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.